Skip to main
KIDS
KIDS logo

OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics (KIDS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

OrthoPediatrics Corp has demonstrated significant growth, with Trauma & Deformity sales increasing by 17.3% year-over-year to $44.1 million, reflecting robust market demand that exceeded estimates. Additionally, the company achieved a strong adjusted EBITDA margin improvement of 280 basis points year-over-year, signaling enhanced operational efficiency. Management's confidence in revenue growth, driven by potential upswings in distributive productivity and product uptake, sets a positive long-term outlook for the company's financial performance.

Bears say

The analysis indicates several fundamental concerns regarding OrthoPediatrics Corp's stock, particularly highlighting a slowdown in revenue growth, which declined to 12.2% in the third quarter of 2025 from 15.7% in the previous quarter. Additionally, the company's recent deployment of product sets decreased from $17.2 million to $16.0 million over the trailing twelve months, further signaling weaker sales performance. Coupled with lowered fiscal year 2025 revenue guidance of $233.5 million to $234.5 million, these factors collectively contribute to a more pessimistic outlook due to potential challenges in product launches and productivity gains among distributors.

OrthoPediatrics (KIDS) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OrthoPediatrics (KIDS) Forecast

Analysts have given OrthoPediatrics (KIDS) a Buy based on their latest research and market trends.

According to 8 analysts, OrthoPediatrics (KIDS) has a Buy consensus rating as of Nov 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OrthoPediatrics (KIDS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.